Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

NCT02437591 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.

NCT NCT02437591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02437591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
Lead sponsor
Astellas Pharma Europe Ltd.
Phase
Phase 4
Overall status
Completed
Start date
August 13, 2015
Completion date
October 24, 2016
Enrollment
25 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection (cdi), inflammatory bowel disease (ibd)